Economic Evaluation of Sintilimab Plus Bevacizumab Versus Sorafenib as a First-line Treatment for Unresectable Hepatocellular Carcinoma
Ting Zhou, Yingdan Cao, Xintian Wang, Lan Yang, Zijing Wang, Aixia Ma, Hongchao Li
Topics & Concepts
MedicineSorafenibHepatocellular carcinomaBevacizumabInternal medicineOncologyRheumatologyCarcinomaChemotherapyHepatocellular Carcinoma Treatment and PrognosisEconomic and Financial Impacts of CancerHealth Systems, Economic Evaluations, Quality of Life